Get started
Author

Nunzio Belluardo

The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches
2020 · Fabio Salvatore Macaluso, Walter Fries, et al. · Inflammatory Bowel Diseases · 49
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases
2018 · Fabio Salvatore Macaluso, Rosalba Orlando, et al. · Digestive and Liver Disease · 45
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn’s Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease
2018 · Fabio Salvatore Macaluso, Walter Fries, et al. · Journal of Crohn s and Colitis · 36
Effectiveness and safety of vedolizumab in biologically naïve patients: A real‐world multi‐centre study
2020 · Fabio Salvatore Macaluso, Walter Fries, et al. · United European Gastroenterology Journal · 34
PDF
Persistence on Anti-Tumour Necrosis Factor Therapy in Older Patients with Inflammatory Bowel Disease Compared with Younger Patients: Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2020 · the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD), Serena Porcari, et al. · Drugs & Aging · 28
SPOSAB ABP 501: A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021 · Fabio Salvatore Macaluso, Maria Cappello, et al. · Journal of Gastroenterology and Hepatology · 23
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease
2020 · Fabio Salvatore Macaluso, Marco Ventimiglia, et al. · Journal of Gastroenterology and Hepatology · 23
PDF
Ustekinumab is a promising option for the treatment of postoperative recurrence of Crohn's disease
2023 · Fabio Salvatore Macaluso, Mauro Grova, et al. · Journal of Gastroenterology and Hepatology · 20
PDF
Vedolizumab may be an effective option for the treatment of postoperative recurrence of Crohn's disease
2021 · Fabio Salvatore Macaluso, Maria Cappello, et al. · Digestive and Liver Disease · 15
The Importance of Disease Prevalence in Assessing the Diagnostic Value of a Test: Endoscopic Markers in Celiac Disease
2013 · Salvatore Pellegrino, Federica Furfaro, et al. · Digestion · 12
Safety and effectiveness of tofacitinib in ulcerative colitis: Data from TOFA-UC, a SN-IBD study
2023 · Fabio Salvatore Macaluso, Elvira D'Antonio, et al. · Digestive and Liver Disease · 11
PDF
T.10.1 Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data From Tofa-uc, a Sn-ibd Study
2023 · F.S. Macaluso, E. D'Antonio, et al. · Digestive and Liver Disease · 2
P305 Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
2021 · F Macaluso, W Fries, et al. · Journal of Crohn s and Colitis · 2
P425 SPOSIB SB2: a Sicilian prospective observational study of patients with inflammatory bowel disease treated with infliximab biosimilar SB2
2020 · F S Macaluso, W Fries, et al. · Journal of Crohn s and Colitis · 2
Comparative effectiveness and safety of tofacitinib and filgotinib in patients with ulcerative colitis: A propensity score-weighted cohort study
2025 · Fabio Salvatore Macaluso, Walter Fries, et al. · Digestive and Liver Disease · 1
Af.51 Vedolizumab May Be an Effective Option for the Management of Postoperative Recurrence of Crohn’s Disease
2021 · F.S. Macaluso, M. Cappello, et al. · Digestive and Liver Disease · 1
PDF
Sposab Abp 501 - a Sicilian Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Adalimumab Biosimilar Abp 501
2021 · Fabio Salvatore Macaluso, Maria Cappello, et al. · Gastroenterology · 1
P577 A propensity score-matched comparison of infliximab and adalimumab in naïve and non-naïve patients with Crohn’s disease
2018 · A Orlando, F S Macaluso, et al. · Journal of Crohn s and Colitis · 1
P412 The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacy
2017 · A. Orlando, F.S. Macaluso, et al. · Journal of Crohn s and Colitis · 1
T.06.2 Ustekinumab Is a Promising Option for the Treatment of Postoperative Recurrence of Crohn's Disease
2023 · F.S. Macaluso, M. Grova, et al. · Digestive and Liver Disease
P396 Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn’s Disease
2023 · F S Macaluso, M Grova, et al. · Journal of Crohn s and Colitis
PDF
P570 Safety and Effectiveness of Tofacitinib in Ulcerative Colitis: Real-world Data from TOFA-UC, a SN-IBD Study
2023 · F S Macaluso, E D'Antonio, et al. · Journal of Crohn s and Colitis
PDF
Af.57 Sposab Abp 501: a Sicilian Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Adalimumab Biosimilar Abp 501
2021 · F.S. Macaluso, M. Cappello, et al. · Digestive and Liver Disease
P288 Vedolizumab May Be An Effective Option For The Management Of Postoperative Recurrence Of Crohn’s Disease
2021 · F S Macaluso, M Cappello, et al. · Journal of Crohn s and Colitis
PDF
P436 SPOSAB ABP 501 - A Sicilian Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Adalimumab Biosimilar ABP 501
2021 · F Macaluso, M Cappello, et al. · Journal of Crohn s and Colitis
Works count: 39
Citation count: 307
H-index: 11
I10-index: 11
Year
Topic
Type